Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Mallinckrodt
Express Scripts
Baxter
Medtronic

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ibodutant

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Ibodutant: Patents, clinical trial progress, indications

Ibodutant is an investigational drug.

There have been 5 clinical trials for Ibodutant. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2015.

The most common disease conditions in clinical trials are Syndrome, Irritable Bowel Syndrome, and Diarrhea. The leading clinical trial sponsors are Menarini Group and [disabled in preview].

There are three US patents protecting this investigational drug and one hundred and five international patents.

Recent Clinical Trials for Ibodutant
TitleSponsorPhase
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)Menarini GroupPhase 3
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)Menarini GroupPhase 3
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)Menarini GroupPhase 3

See all Ibodutant clinical trials

Clinical Trial Summary for Ibodutant

Top disease conditions for Ibodutant
Top clinical trial sponsors for Ibodutant

See all Ibodutant clinical trials

US Patents for Ibodutant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ibodutant   Start Trial Linear basic compounds having NK-2 antagonist activity and formulations thereof Menarini Ricerche S.P.A. (Pomezia, IT)   Start Trial
Ibodutant   Start Trial Pharmaceutical compositions based on NK2 antagonists for pediatric use Laboratori Guidotti S.p.A. (Pisa, IT)   Start Trial
Ibodutant   Start Trial Process for the preparation of ibodutant (MEN15596) and related intermediates Malesci Istituto Farmacobiologico S.p.A. (Bagno A Ripoli, IT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Mallinckrodt
Merck
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.